Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
Aspire Biopharma (Nasdaq:ASBP) reported its participation at CPHI Frankfurt (Oct 27-30, 2025), where management held 16 formal face-to-face meetings and dozens of informal discussions with global pharmaceutical companies including Bayer, Deva Holdings, Abiogan, Key Pharmaceuticals, TGC Health, Instapill, Zerion and others.
The company highlighted positive final investigational study results for its sublingual high-dose aspirin showing higher and faster mean plasma concentrations of ASA versus chewed aspirin, which the company says is relevant for potential treatment of suspected acute myocardial infarction. Aspire said discussions focused on technical collaboration, licensing, joint ventures and commercial partnerships to accelerate development and market readiness.
Aspire Biopharma (Nasdaq:ASBP) ha riferito la sua partecipazione al CPHI Francoforte (27-30 ottobre 2025), dove la direzione ha svolto 16 incontri faccia a faccia formali e decine di discussioni informali con aziende farmaceutiche globali tra cui Bayer, Deva Holdings, Abiogan, Key Pharmaceuticals, TGC Health, Instapill, Zerion e altri.
L'azienda ha evidenziato risultati finali positivi dello studio clinico investigazionale per il suo aspirina sublinguale ad alta dose, che mostrano concentrazioni plasmatiche medie di ASA più alte e più rapide rispetto all'aspirina masticata, cosa che l'azienda ritiene rilevante per un potenziale trattamento dell'infarto acuto sospetto. Aspire ha detto che le discussioni si sono concentrate su collaborazioni tecniche, licenze, joint ventures e partnership commerciali per accelerare lo sviluppo e la prontezza al mercato.
Aspire Biopharma (Nasdaq:ASBP) informó su participación en CPHI Frankfurt (del 27 al 30 de oct de 2025), donde la dirección sostuvo 16 reuniones formales cara a cara y decenas de conversaciones informales con empresas farmacéuticas globales, entre ellas Bayer, Deva Holdings, Abiogan, Key Pharmaceuticals, TGC Health, Instapill, Zerion y otros.
La empresa resaltó resultados positivos finales del estudio investigacional para su aspirina sublingual de alta dosis, que muestran concentraciones plasmáticas medias de ASA más altas y más rápidas en comparación con la aspirina masticada, lo que la empresa dice que es relevante para un posible tratamiento de un infarto agudo de miocardio sospechado. Aspire dijo que las discusiones se centraron en colaboraciones técnicas, licencias, empresas conjuntas y asociaciones comerciales para acelerar el desarrollo y la preparación para el mercado.
Aspire Biopharma (Nasdaq:ASBP) 프랑크푸르트 CPHI 행사에 참석했다고 발표했다(2025년 10월 27-30일), 경영진은 16건의 형식적인 대면 회의와 Bayer, Deva Holdings, Abiogan, Key Pharmaceuticals, TGC Health, Instapill, Zerion 등 글로벌 제약사들과의 수십 건의 비공식 논의를 가졌다.
회사는 자사의 고용량 아스피린 서링구얼 제형에 대한 최종 연구 결과가 양호하다고 강조하며 ASA의 혈장 평균 농도가 더 높고 더 빠르게 나타난다고 밝혔다. 이는 의심되는 급성 심근경색의 잠재적 치료와 관련이 있다고 회사는 말한다. Aspire는 개발을 가속화하고 시장 준비를 빠르게 하기 위한 기술 협력, 라이선스, 공동 벤처 및 상업적 파트너십에 초점이 맞춰진 논의가 이뤄졌다고 말했다.
Aspire Biopharma (Nasdaq:ASBP) a annoncé sa participation au CPHI Francfort (27-30 octobre 2025), où la direction a tenu 16 réunions en face à face formelles et des dizaines de discussions informelles avec des entreprises pharmaceutiques mondiales, notamment Bayer, Deva Holdings, Abiogan, Key Pharmaceuticals, TGC Health, Instapill, Zerion et d'autres.
L'entreprise a mis en évidence des résultats positifs finaux de l'étude investigatoire pour son aspirin sublingual à dose élevée, montrant des concentrations plasmatiques moyennes de l'ASA plus élevées et plus rapides par rapport à l'aspirine mastiquée, ce que l'entreprise dit être pertinent pour un traitement potentiel d'un infarctus du myocarde suspecté. Aspire a indiqué que les discussions se concentraient sur la collaboration technique, les licences, les coentreprises et les partenariats commerciaux pour accélérer le développement et la préparation au marché.
Aspire Biopharma (Nasdaq:ASBP) berichtete über seine Teilnahme an der CPHI Frankfurt (27.-30. Okt. 2025), bei der das Management 16 formelle persönliche Meetings und Dutzende informeller Gespräche mit weltweiten Pharmaunternehmen führte, darunter Bayer, Deva Holdings, Abiogan, Key Pharmaceuticals, TGC Health, Instapill, Zerion und weitere.
Das Unternehmen hob positive Endergebnisse der investigativen Studie für sein sublinguales Hochdosis-Aspirin hervor, die höhere und schnellere mittlere Plasmakonzentrationen von ASA im Vergleich zu gekauten Aspirin zeigen, was das Unternehmen als relevant für eine potenzielle Behandlung eines vermuteten akuten Myokardinfarkts ansieht. Aspire sagte, dass die Diskussionen sich auf technische Zusammenarbeit, Lizenzen, Joint Ventures und kommerzielle Partnerschaften konzentrierten, um die Entwicklung und Marktreife zu beschleunigen.
Aspire Biopharma (Nasdaq:ASBP) أبلغت عن مشاركتها في معرض CPHI فرانكفورت (27-30 أكتوبر 2025)، حيث عقدت الإدارة 16 اجتماعاً وجهاً لوجه رسمياً وآلاف من المناقشات غير الرسمية مع شركات أدوية عالمية بما في ذلك باير، Deva Holdings، Abiogan، Key Pharmaceuticals، TGC Health، Instapill، Zerion وغيرها.
سلطت الشركة الضوء على نتائج إيجابية نهائية للدراسة التجريبية لدوائها من الأسبرين عالي الجرعة تحت اللسان، والتي أظهرت تركيزات بلازما ASA المتوسطة أعلى وأسرع مقارنة بالأسبرين الممضوغ، وهو ما تقول الشركة إنه ذا صلة بعلاج محتمل لاحتشاء عضلة القلب الحاد المشبوه به. قالت Aspire إن المناقشات ركزت على التعاون التقني، والترخيص، والمشروعات المشتركة والشراكات التجارية لتسريع التطوير والاستعداد للسوق.
- Study: higher and faster mean ASA plasma concentrations versus chewed aspirin
- Conducted 16 formal face-to-face meetings at CPHI Frankfurt
- Engaged with major industry names including Bayer and multiple global players
- No signed licensing or joint‑venture agreements announced from CPHI interactions
- No commercial timelines, financial terms, or regulatory approvals disclosed
Insights
Aspire reports positive pharmacokinetic results and active partnership discussions at CPHI; outcome depends on formal licensing or joint‑venture agreements.
Aspire Biopharma presented its lead sublingual high‑dose aspirin at CPHI Frankfurt (
The business case hinges on converting interest into binding partnerships and on follow‑up development steps. The report lists named potential partners and notes interest, but it does not disclose executed licensing terms, regulatory plans, or additional clinical endpoints beyond pharmacokinetics. Those missing items are essential to assess commercial value and regulatory risk.
Watch for concrete milestones such as signed licensing or joint‑venture agreements, disclosures of regulatory strategy or pivotal clinical endpoints, and any planned studies that link the pharmacokinetic benefit to clinical outcomes; expect these items to appear before commercial value is realized, likely over the next 6–24 months.
ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced its successful participation in the CPHI Frankfurt trade show, the world's largest pharmaceutical event. The Company engaged in numerous strategic discussions with global pharmaceutical companies regarding technical collaboration and licensing opportunities for its lead product candidate, a novel sublingual high-dose aspirin.
Held in Frankfurt, Germany, from October 27-30, CPHI unites professionals across the entire pharma supply chain to collaborate, build relationships, and drive business forward. This year's event hosted over 63,000 attendees from 160 countries and featured 2,400 exhibitors. During the conference, Aspire's management team conducted 16 formal, face-to-face meetings and dozens of informal conversations with interested parties. Notable discussions were held with representatives from major industry players including Deva Holdings, Abiogan, Bayer, Key Pharmaceuticals, AI Branding, TGC Health, Instapill, and Zerion, among others.
Steve Quesenberry, who serves as counsel for Aspire and represented the Company at the event, stated, "Attending CPHI Frankfurt was an invaluable experience for Aspire. The sheer scale of the event is impressive, but the real value was in the quality of our interactions. Having sixteen face-to-face meetings, in addition to many other promising conversations, allowed us to directly showcase the compelling clinical data for our sublingual high-dose aspirin. The reception was overwhelmingly positive, and these discussions with major industry players are a critical step toward establishing the strategic partnerships needed to bring our innovative product to a global market."
The primary focus of these discussions was Aspire's sublingual high-dose aspirin, which recently reported positive final results from its investigational study. The study demonstrated that Aspire's formulation produced higher and more rapid mean plasma concentrations of acetylsalicylic acid (ASA), the active antiplatelet form of aspirin, compared to chewed aspirin tablets. This is critically important for its potential use in treating suspected acute myocardial infarction (AMI), or heart attack.
Kraig Higginson, Interim CEO of Aspire Biopharma, stated, "Our team was pleased to establish introductions that opened discussions on potential joint venture and licensing opportunities with leading pharmaceutical companies. The strong interest we received at CPHI Frankfurt reinforces our strategy and highlights the substantial potential of our drug‑delivery platform. We are now focused on building partnerships that can accelerate development and commercial readiness. These collaborations will play a crucial role in bringing our innovative delivery solutions to market efficiently and safely, maximizing the commercial value of our lead program."
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.
For more information, please visit www.aspirebiolabs.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Aspire Biopharma Holdings, Inc.
Contact
Brett Maas
Hayden IR: (646) 536-7331
brett@haydenir.com
James Carbonara
Hayden IR: (646)-755-7412
james@haydenir.com
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Aspire Biopharma announce at CPHI Frankfurt on November 6, 2025 regarding ASBP?
What were the key clinical results Aspire highlighted for ASBP's sublingual high-dose aspirin?
Which companies did Aspire Biopharma meet with at CPHI Frankfurt relevant to ASBP partnership talks?
Does Aspire have any announced deals or timelines for ASBP after CPHI Frankfurt?
How is Aspire positioning the sublingual high-dose aspirin for acute myocardial infarction (AMI)?
